SIJI SAMUEL: Open Payments
NPI 1801567359 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$563 in 28 payments from 10 companies in 2025. Trend: 2023 $927 · 2024 $527 · 2025 $563
Food & beverage: $563
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $199 |
| Veloxis Pharmaceuticals, Inc. | 3 | $91 |
| Alexion Pharmaceuticals, Inc. | 4 | $79 |
| NxStage Medical, Inc. | 2 | $39 |
| Apellis Pharmaceuticals, Inc. | 2 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $29 |
| KYOWA KIRIN, INC. | 1 | $25 |
| Ardelyx, Inc. | 1 | $25 |
| CorMedix Inc. | 1 | $24 |
| Travere Therapeutics, Inc. | 1 | $20 |
Products named: FARXIGA, ENVARSUS, ULTOMIRIS, NXSTAGE SYSTEM ONE, CRYSVITA, IBSRELA, DEFENCATH, Empaveli.
Industry payments across TX — which companies pay providers there.
